**Core tip:** Our manuscript reports on 38 patients with unresectable distal malignant biliary obstruction (MBO) treated with a newly developed 14-mm diameter Niti-S biliary uncovered metal stent. The results could show the stent is preferable for the palliate treatment of unresectable distal MBO because of a low rate of recurrent biliary obstruction, no migration, a low rate of other complications, and a high success rate of placement.

INTRODUCTION
============

Endoscopic transpapillary biliary stent placement is an established procedure for relieving jaundice and treating cholangitis in patients with malignant biliary obstruction (MBO). The treatment can contribute to the improvement of quality of life and prognosis of patients with unresectable MBO. A plastic tube stent had been widely used as the first generation of stent treatment for MBO\[[@B1]\], although it had the issue of being easily occluded due to its small diameter of 7 to 11 Fr.

In the last decade of the 20^th^ century, a self-expandable metal stent (SEMS) with a wider diameter of 8 to 10 mm without being covered, *i.e*., an uncovered SEMS (UCSEMS), was developed with recognition for its efficacy in relieving jaundice with long term patency\[[@B2]-[@B5]\]. However, stent occlusion due to tumor ingrowth and food impaction was frequently experienced and thus requires a solution.

A covered SEMS (CSEMS) was produced to prevent tumor in growth through the stent mesh. The advantage of the CSEMS was long-term patency because the membrane could prevent tumor in growth\[[@B6]\]; however, this stent type could not perfectly avoid occlusion as sludge or food impaction was encountered, or stent migration easily occurred\[[@B7]-[@B9]\]. It was hypothesized that the larger stent diameter could contribute to maintaining a longer patency with supportive evidence by some reports\[[@B10]-[@B12]\]. Recently, a CSEMS with a 12-mm diameter, SUPREMO 12, was developed and verified this hypothesis\[[@B13]\]. However, easy migration of CSEMS remained an issue despite the larger diameter\[[@B13]\].

To prevent migration, an UCSEMS is preferable\[[@B6],[@B14],[@B15]\] to a CEMS, because the uncovered mesh of the stent is embedded in the bile duct wall and makes the stent keep still. However, occlusion due to tumor in growth remains unresolved for treatment by an UCSEMS. If an UCSEMS stent had a larger diameter, it could be expected to keep the bile flow despite tumor ingrowth and maintain a longer patency and a UCSEMS with a large diameter of 14 mm, Niti-S 14 (Taewoong Medical CO., Ltd., Seoul, South Korea), was developed. Herein, the efficacy and safety of the Niti-S 14 for MBO was evaluated.

MATERIALS AND METHODS
=====================

Study design
------------

We retrospectively evaluated the efficacy and safety of Niti-S 14, placed transpapillarily for consecutive and unresectable MBO from April 2014 to May 2016 in the following 3 institutions; Shizuoka General Hospital, Gifu Municipal Hospital, and Hamamatsu University Hospital. The outcome measures were rate of technical and functional achievement, rate of recurrent biliary obstruction (RBO)\[[@B16]\], time to RBO (TRBO)\[[@B16]\], survival time, and stent-related adverse events. Diagnosis of MBO was established by laboratory data, imaging findings, and histopathological examinations. Stage of the disease was determined by the findings of computed tomography or endoscopic ultrasonography.

Patients
--------

Thirty-eight patients with MBO of the middle to lower part of the extrahepatic bile duct and expectance of survival for longer than 2 mo underwent treatment for MBO by Niti-S 14 placement (Table [1](#T1){ref-type="table"}). Twenty-one males and 17 females were included with median age of 70 (range, 52-90) years. All patients had fair activity of daily living (ECOG-PS grade 0-2). Those with post-gastrectomy state (Billroth II or Roux-en-Y reconstruction) were excluded from candidates for this treatment. Causes of obstruction of the extrahepatic bile duct were pancreatic cancer, bile duct cancer, and metastatic lymphadenopathy in 36, 1, and 1 patients, respectively. Thirty-seven patients belonged to the clinical stage IV of the UICC TNM classification, and the remaining one patient was stage III. The median tumor size was 33 (range, 13-70) mm and the median length of the biliary stricture was 27 (range, 10-60) mm. The median diameter of the proximal bile duct was 13.5 (range, 7-20) mm.

###### 

Patient characteristics

                                                    ***n* = 38**
  ------------------------------------------------- --------------
  Men/women                                         21/17
  Age (yr)                                          70 (52-90)
  PS (0/1/2)                                        8/21/9
  Diagnosis                                         
  Pancreatic cancer                                 36
  Bile duct cancer                                  1
  Metastatic nodes                                  1
  Clinical stage III/IV                             1/37
  Tumor size (mm)                                   33 (13-70)
  Length of the biliary stricture (mm)              27 (10-60)
  Maximum diameter of the proximal bile duct (mm)   13.5 (7-20)

PS: Performance status.

Niti-S 14
---------

Niti-S 14 is a newly developed UCSEMS with braided structure made from nitinol, and a large diameter of 14 mm with a length of 60 or 80 mm (Figure [1](#F1){ref-type="fig"}). The outer diameter of the delivery sheath was 9 Fr. A 0.035-inch guide-wire can be used for introducing the stent into the bile duct.

![Niti-S 14 appearance with a braided structure made from nitinol, and a large diameter of 14 mm with a length of 60 or 80 mm.](WJGE-10-16-g001){#F1}

Stent placement
---------------

In all patients, Niti-S 14 was placed through the duodenum major papilla during endoscopic retrograde cholangiopancreatography. A 60- or 80-mm stent length was selected according to the length of the stricture. The distal end of the stent was placed in the duodenum (Figure [2](#F2){ref-type="fig"}). Endoscopic sphincterotomy (EST) was performed at the discretion of the operator, mainly to avoid post-ERCP pancreatitis. The stricture was not dilated by a balloon before stent placement. Niti-S 14 was used as the primary treatment for MBO in principal.

![Stent placement of Niti-S 14 after sphincterotomy in pancreatic cancer. A: Endoscopic view; B: Picture of endoscopic retrograde pancreatocholangiography.](WJGE-10-16-g002){#F2}

Following-up and adverse events definition
------------------------------------------

Clinical signs and symptoms and biochemical parameters of liver function and inflammation (aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma glutamyl transpeptidase, total and direct bilirubin, and C-reactive protein levels) were evaluated at least monthly. Complications were defined according to the Tokyo Criteria 2014\[[@B14]\]. According to these criteria, RBO was defined as occlusion or symptomatic migration, and TRBO was the interval between stent placement and RBO, which was calculated instead of patency. The definition of post-ERCP pancreatitis (PEP) was new or worsened abdominal pain with serum amylase ≥ threefold the upper limit of normal, measured \> 24 h after the procedure. Acute cholecystitis was diagnosed when a fever \> 38 °C or right upper abdominal pain occurred with supportive imaging studies.

Statistical analysis
--------------------

Stent patency duration and survival time were estimated by the Kaplan-Meier method. Continuous variables were analyzed using one-way analysis of variance, and categorical and binary variables were analyzed using Fisher's exact test. All statistical tests were two-tailed and assessed at a 0.05 probability level. All analyses were performed using SPSS software, version 18.0 (SPSS Inc., Chicago, Illinois, United States).

RESULTS
=======

Technical and functional achievement
------------------------------------

In all patients, stent placement was successful (technical success rate = 100%) (Table [2](#T2){ref-type="table"}). Stents with a length of 60 mm and 80 mm were selected for and placed in 14 and 24 patients, respectively. EST was performed before placement in 20 patients (52.6%) because the orifice of the major papilla was small with incomplete obstruction of the main pancreatic duct by pancreatic head cancer in 18 and without pancreatic head cancer in 2. In all patients, total bilirubin level deceased and normalized within 14 d and functional success (defined as 50% decrease in or normalization of the bilirubin level within 14 d of stent placement\[[@B14]\]) was achieved (functional success rate = 100%). Stent placement was performed after relieving jaundice by retrograde biliary drainage and naso-biliary drainage (NBD) in 9 (23.7%) and 2 (5.3%) patients, respectively, and for replacing a previously placed CSEMS with smaller diameter due to cholangitis in 5 (13.2%).

###### 

Results of stent placement

                                     ***n* (%)**
  ---------------------------------- -------------------
  Technical success                  38 (100)
  Functional success                 38 (100)
  Selected stent length (60/80 mm)   14/24 (36.8/63.2)
  Endoscopic sphincterotomy          20 (52.6)
  Previous drainage (RBD/NBD)        9/2 (23.7/5.3)
  Replacement for CSEMS              5 (13.2)

RBD: Retrograde biliary drainage; NBD: Naso-biliary drainage; CSEMS: Covered self-expandable metal stent.

RBO, TRBO, and survival time
----------------------------

Two patients (5.3%) experienced RBO due to tumor ingrowth and overgrowth just above the upper end of the stent (Table [3](#T3){ref-type="table"}). Jaundice with liver injury was recognized on 164 d and 215 d in two patients. The median TRBO was 190 (range, 164-215) d. RBO was treated by placing a CSEMS endoscopically across the obstructed biliary portion through the previously placed Niti-S 14. In the patient with tumor overgrowth, the Niti-S 14 was patent on endoscopic retrograde cholangiography, and endoscopic observation revealed coverage of the inside wall of the stent by a hyperplastic mucosal tissue (Figure [3](#F3){ref-type="fig"}).

###### 

Retrograde biliary drainage, time to retrograde biliary drainage, and survival time

                                             ***n* (%)**
  ------------------------------------------ ---------------
  RBO                                        2 (5.3)
  Tumor ingrowth                             1 (2.6)
  Tumor overgrowth                           1 (2.6)
  Median TRBO (d)                            190 (164-215)
  Non-obstruction rates of 3, 6, 12 mo (%)   100, 91, 78
  Median survival time (d)                   120 (18-502)

RBO: Recurrent biliary obstruction; TRBO: Time to recurrent biliary obstruction.

![Endoscopic view of the duodenal major papilla after Niti-S 14 placement. The bile duct cavity is maintained despite bile duct mucosa or tumor growth into the stent.](WJGE-10-16-g003){#F3}

The non-obstruction rates of 3, 6 and 12 mo were 100%, 91% and 78%, respectively (Figure [4](#F4){ref-type="fig"}). The median survival time was 120 (range, 18-502) d (Figure [5](#F5){ref-type="fig"}).

![Kaplan-Meier analysis of stent patency. The non-RBO rates of 3, 6 and 12 mo were 100%, 91% and 78%, respectively. RBO: Recurrent biliary obstruction.](WJGE-10-16-g004){#F4}

![Kaplan-Meier analysis of survival. The median survival time was 120 d.](WJGE-10-16-g005){#F5}

Adverse events
--------------

Adverse events occurred in 11 patients (28.9%). RBO was recognized in two patients (5.3%) in the manner of tumor ingrowth and tumor overgrowth as described above. Adverse events other than RBO occurred as follows (Table [4](#T4){ref-type="table"}): Acute cholecystitis, PEP, hemobilia, fever without exacerbation of liver injury, and liver abscess in 4 (10.3%), 3 (7.9%), 2 (5.3%), 1 (2.6%) and 1 (2.6%), respectively. Stent migration was not observed. Bile duct perforation was not experienced despite of the large diameter of 14 mm. Acute cholecystitis occurred on day 3, 32, 217 and 487 after stent placement in four respective patients and the inflamed and swollen gallbladder was punctured percutaneously without placing a percutaneous drainage tube with the infected bile aspirated from the gallbladder. PEP was diagnosed within the day after placement but was mild and treated by conservative ways. In 2 patients, hemobilia was recognized by examining the cause of hematemesis on day 92 in one and 119 in the other, and a fully covered EMS (WallFlex stent, 10 mm × 60 mm, Boston Scientific Corp, Natick, Mass, United States) was placed inside the 14-mm Niti-S with achievement of hemostat. In patients with cholangitis due to migration of a previously placed CSEMS, we swapped the previously placed stent to the Niti-S 14 in 5 patients. Among them, one patient had persistent high fever after replacement without cholecystitis despite the relief of hepatobiliary dysfunction; the patient was treated by antibiotic administration for 10 d. One patient experienced liver abscess, which was diagnosed on day 17 because of high fever, and was treated by percutaneous puncture with drainage tube placement. However, the patient died the next day due to septic shock with abscess rupture toward the peritoneal cavity.

###### 

Complications other than recurrent biliary obstruction

  **Complications**                            **11/38 (28.9%)**   **Time to event (d)**
  -------------------------------------------- ------------------- -----------------------
  Acute cholecystitis                          4 (10.3)            3, 32, 217, 487
  PEP                                          3 (7.9)             1 (each)
  Hemorrhage                                   2 (5.3)             92, 119
  Fever without exacerbation of liver injury   1 (2.6)             1
  Liver abscess                                1 (2.6)             17

PEP: Post-ERCP pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography.

DISCUSSION
==========

The ideal stent is free from occlusion, migration, and other adverse events. Especially, occlusion and migration are major problems for treating MBO by SEMS. To resolve these complications, the 14-mm Niti-S^TM^ biliary uncovered-stent (Niti-S 14) was developed, which was characterized by an uncovered feature and a large diameter of 14 mm. On development, the diameter of 14 mm was expected to be large enough to prevent occlusion despite tumor ingrowth. In this study, the results support the superiority of the Niti-S 14 with a low RBO rate, lack of migration, low rates of other complications, and a high technical success rate.

Low RBO rate
------------

Stent occlusion was recognized in just 2 patients (5.3%) with Niti-S 14, and the 6-mo stent patency was 91%. Previous reports described stent occlusion rates of 18%-38% using conventional types of UCSEMS with a diameter of 10 mm\[[@B5],[@B6],[@B15],[@B16]\]. If our result of 5.3% in Niti-S 14 is comparable with that of previous reports, it is because of low incidence of tumor ingrowth. In patients with Niti-S 14, endoscopic observation of the stent showed mucosa or tumor tissue growth into the inside of the stent, which is the same finding observed with the conventional type of UCSEMS, while the stent was not occluded because the large 14-mm diameter could maintain the stent cavity. On the other hand, tumor overgrowth was recognized in one patient. The length of the stent might be insufficient to prevent bile duct obstruction due to overgrowth in patients with a large tumor, and tumor overgrowth resulting from RBO could be resolved by a longer Niti-S 14.

In CSEMS, stent occlusion by tumor ingrowth is rarely experienced, while tumor overgrowth, food impaction, and migration were relatively common causes of stent occlusion, with reported occlusion rates of 14%-23% in a fully-covered SEMS\[[@B6],[@B15]\], 5.8%-29% in a partially covered SEMS\[[@B16],[@B17]\], and 26% in SUPREMO 12\[[@B13]\]. In comparing our result with those of previous reports on CSEMS, an RBO rate of 5.3% was preferable.

Six-month stent patency was also evaluated previously, and reported to be 78%-90%, 70%-94%, 63%-91%, and 50% in a conventional type of UCSEMS\[[@B5],[@B6],[@B15],[@B16]\], fully-covered SEMSs\[[@B6],[@B18],[@B19]\], partially-covered SEMS\[[@B16],[@B17]\], and SUPREMO 12\[[@B13]\], respectively. Our result of 91% using Niti-S 14 was comparable or superior to that of these previous studies.

No migration
------------

Niti-S 14 is an uncovered, which is a characteristic that prevents migration. A lack of migration also contributes to low RBO rate. RBO in patients with CSEMS placement was frequently due to stent migration in previous reports\[[@B13],[@B16],[@B20]\]; this complication was also observed if a partially-covered SEMS was used\[[@B20]\]. To prevent migration, selecting a UCSEMS may be desirable, and the other issue of tumor ingrowth should be resolved. As mentioned above, the large diameter of 14 mm could provide a solution for this problem.

Low other adverse event rates
-----------------------------

Acute cholecystitis and PEP are relatively common adverse events after placing an SEMS with rates of 0%-10% and 0%-8%, respectively, in previous reports\[[@B6],[@B15]-[@B23]\], and were experienced in 10.3% and 7.9% of patients with Niti-S 14, respectively. Despite the large diameter of the stent, the incidences were almost equal to those of previous reports. After placing Niti-S 14, EST was performed in 18 patients with pancreatic head cancer or without pancreatic head cancer in 2 for the purpose of preventing PEP, because the main pancreatic duct was not completely obstructed by the tumor and the orifice of the major papilla was small. As a result, PEP occurred in 5% of patients with EST and 11% of those without EST. In patients with EST, the incidence of PEP tended to be low, but it was not statistically significant. Those results suggest that the large diameter of a stent is not responsible for PEP and EST does not contribute to preventing PEP. Our result of performing EST to prevent PEP does not contradict the previous report describing that EST does not effectively act to prevent PEP in patients undergoing stent placement\[[@B24]\]. It is suggested that several factors besides obstructing a pancreatic duct orifice by a stent are responsible for PEP.

High technical success rate
---------------------------

We succeeded placement of SEMS in all patients using Niti-S 14. Despite the large diameter of the stent, the delivery system of Niti-S 14 is thin (9 Fr) and soft. The characteristics of the Niti-S 14 delivery system could provide an optimal effect for endoscopic introduction of the delivery system into the bile duct through the duodenal papilla.

Although these preferable results were obtained in placing Niti-S 14, our study showed that patients undergoing Niti-S 14 placement had a shorter survival time of 113 (range, 18-502) d compared with those of previous reports\[[@B14],[@B15],[@B20]\]. In Niti-S 14, almost all patients had pancreatic cancer and the levels of CA19-9 tended to be higher. This tendency might lead to shorter survival, because, as it is widely known, pancreatic cancer has a poor prognosis and high CA19-9 levels indicate advanced tumor progression\[[@B25]\]. On the other hand, it cannot be denied that the larger diameter were responsible for shorter survival time. The problem of the shorter survival time should be resolved by further randomized control studies comparing Niti-S 14 with other types of stent. Another problem regarding the shorter survival time is this shorter observation time might lead to an apparent low rate of RBO.

In our study, persistent high fever was observed after replacing the CSEMS for Niti-S 14 because of cholangitis due to RBO from migration. Acute cholecystitis was not recognized in the patient. We speculate that this complication might be induced by an enwrapped infected bile duct epithelium, probably with micro-abscess. Moreover, we experienced one patient die on day 18 due to liver abscess in Niti-S 14. The abscess was large at diagnosis, and the possibility that the abscess had already developed by the time of stent placement was presumed.

In conclusion, Niti-S 14 is considered to be a preferable SEMS because of a low rate of RBO, no migration, a low rate of other complications, and a high success rate. However, this study is limited because of the small number of patients and the retrospective evaluation. Further prospective, multicenter, international double-blind controlled studies, comparing different type of stents (*e.g*., UCSEMS *vs* partially covered SEMS) are necessary, in order to standardize the best drainage policy.

ARTICLE HIGHLIGHTS
==================

Background
----------

Recurrent biliary obstruction (RBO) due to tumor ingrowth or migration remains to be resolved in endoscopic transpapillary biliary stent placement for malignant biliary obstruction (MBO).

Research frontiers
------------------

It was expected that an uncovered self-expandable metal stent with a large diameter could prevent RBO.

Innovations and breakthroughs
-----------------------------

Niti-S 14 is a large bore and uncovered metal stent, but is safe for treatment for MBO and considered to be a preferable SEMS because of a low rate of RBO with no migration.
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